文献速递其他结缔组织病

癌症合并系统性硬化症患者的免疫检查点抑制剂治疗

Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis.
PubMed 文献 · Semin Arthritis Rheum · 2024-05-04

该研究从约翰霍普金斯硬皮病中心研究登记处纳入8例接受免疫检查点抑制剂(ICI)治疗的癌症合并系统性硬化症(SSc)患者,通过病历回顾和预设定义评估SSc活动度恶化及新发免疫相关不良事件(irAE)。总体SSc症状保持稳定,长期病程的sine型或局限性皮肤型SSc患者无皮肤增厚进展;1例早期弥漫性皮肤型SSc患者出现皮肤增厚加重和肾危象;3例(38%)共发生5次irAE,无irAE相关死亡。

要点

  • 长期病程的sine型或局限性皮肤型SSc患者接受ICI治疗后SSc症状保持稳定且无皮肤增厚进展
  • 1例早期弥漫性皮肤型SSc患者出现皮肤增厚加重和肾危象
  • 3例(38%)患者共发生5次irAE,包括2级腹泻、黏膜炎和皮炎,3级肺炎,4级肾炎,无irAE相关死亡

核心结论

  • ICI治疗在长期病程的sine型或局限性皮肤型SSc患者中耐受良好,irAE常见但通常可控。
  • 早期活动性SSc患者接受ICI治疗可能风险更高,但需要更多研究。

研究设计与样本

  • 从约翰霍普金斯硬皮病中心研究登记处识别接受ICI治疗的癌症合并SSc患者,通过病历回顾和预设定义评估SSc活动度恶化及新发irAE,共纳入8例患者。

主要发现

  • 总体SSc症状在ICI治疗期间和治疗后保持稳定。
  • 长期病程的sine型或局限性皮肤型SSc患者无皮肤增厚进展。
  • 1例早期弥漫性皮肤型SSc患者出现皮肤增厚加重和肾危象。
  • 3例(38%)患者共发生5次irAE:2级腹泻、黏膜炎和皮炎,3级肺炎,4级肾炎。
  • 4级肾炎患者同时发生硬皮病肾危象和免疫检查点相关肾炎,无irAE相关死亡。

局限性

  • 需要更多研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune checkpoint inhibitor (ICI) therapies have dramatically improved outcomes in multiple cancers. ICI's mechanism of action involves immune system activation to augment anti-tumor immunity. Patients with pre-existing autoimmune diseases, such as systemic sclerosis (SSc), were excluded from initial ICI clinical trials due to concern that such immune system activation could precipitate an autoimmune disease flare or new, severe immune related adverse events (irAE). In the present study, we report our experience with ICIs in patients with pre-existing SSc. METHODS: Patients with SSc who received ICI therapy for cancer were identified from the Johns Hopkins Scleroderma Center Research Registry. Through chart review and prespecified definitions, we identified whether patients experienced worsening SSc activity or new irAEs. SSc disease activity worsening was pre-defined as an increase in modified Rodnan skin score (mRSS), new scleroderma renal crisis, progression of interstitial lung disease (ILD) on CT scan, increased Raynaud's phenomenon frequency or severity, new pulmonary hypertension, or myositis flare. IrAEs also included active inflammatory arthritis and dermatitis. RESULTS: Eight patients with SSc who received ICI therapy for cancer were included. Overall, SSc symptoms remained stable during and after ICI therapy. None of the patients with long-standing sine or limited cutaneous SSc (lcSSc) had progressive skin thickening after ICI therapy. One patient, who was early in his diffuse cutaneous SSc (dcSSc) disease course, experienced worsening skin thickening and renal crisis. Three patients (38 %) experienced a total of five irAEs (grade 2: diarrhea, mucositis and dermatitis; grade 3: pneumonitis, and grade 4: nephritis). The patient with grade 4 nephritis developed scleroderma renal crisis and immune checkpoint related nephritis simultaneously. There were no deaths due to irAEs. CONCLUSION: In this study, ICI therapy was well tolerated in patients with longstanding, sine or lcSSc. IrAE were common but generally manageable. Patients with early, active SSc may be at greater risk from ICI therapy, but more research is needed.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Wallwork RS, Kotzin JJ, Cappelli LC, et al. Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis. Semin Arthritis Rheum. 2024. PMID: 38733668. doi:10.1016/j.semarthrit.2024.152460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。